DBV TECHNOLOGIE/S (DBVT) Upgraded by BidaskClub to Hold
DBV TECHNOLOGIE/S (NASDAQ:DBVT) was upgraded by equities research analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued on Tuesday.
Several other brokerages also recently commented on DBVT. Zacks Investment Research raised shares of DBV TECHNOLOGIE/S from a “sell” rating to a “hold” rating in a report on Tuesday, July 17th. ValuEngine raised shares of DBV TECHNOLOGIE/S from a “sell” rating to a “hold” rating in a report on Thursday, August 2nd. Finally, Morgan Stanley raised their price target on shares of DBV TECHNOLOGIE/S from $27.00 to $28.00 and gave the company an “equal weight” rating in a report on Friday, July 13th. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $39.75.
Shares of NASDAQ:DBVT opened at $19.00 on Tuesday. The company has a quick ratio of 4.37, a current ratio of 4.37 and a debt-to-equity ratio of 0.01. DBV TECHNOLOGIE/S has a one year low of $16.65 and a one year high of $50.57. The firm has a market capitalization of $1.05 billion, a price-to-earnings ratio of -5.64 and a beta of 0.92.
About DBV TECHNOLOGIE/S
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.
See Also: Find a Trading Strategy That Works
Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.